Scott Gottlieb
American physician and government administrator (born 1972) / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Scott Gottlieb?
Summarize this article for a 10 year old
Scott Gottlieb (born June 11, 1972) is an American physician, investor, and author who served as the 23rd commissioner of the Food and Drug Administration (FDA) from May 2017 until April 2019. He is presently a senior fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA),[1][2] a member of the board of directors of drug maker Pfizer, Inc[3] and gene sequencing company Illumina, Inc.,[4] and a contributor to the cable financial news network CNBC and the CBS News program Face the Nation.[5] An elected member of the National Academy of Medicine, Gottlieb is the author of The New York Times best selling book Uncontrolled Spread[6] on the COVID-19 pandemic and the national security vulnerabilities that it revealed. His forthcoming book, The Miracle Century: Making Sense of the Cell Therapy Revolution, traces the scientific achievements that propelled progress in cell therapies.
Scott Gottlieb | |
---|---|
23rd Commissioner of Food and Drugs | |
In office May 11, 2017 – April 5, 2019 | |
President | Donald Trump |
Deputy | Anna Abram |
Preceded by | Robert Califf |
Succeeded by | Norman Sharpless |
Personal details | |
Born | (1972-06-11) June 11, 1972 (age 51) East Brunswick, New Jersey, U.S. |
Political party | Republican |
Education | Wesleyan University (BA) Mount Sinai Medical Center (MD) |
Before becoming FDA Commissioner, he was a Clinical Assistant Professor at New York University Grossman School of Medicine, the FDA's Deputy Commissioner for Medical and Scientific Affairs, a venture partner with New Enterprise Associates (NEA) from 2007 to 2017, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare & Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017, prior to joining the FDA as Commissioner in May 2017.